Skip to main content
. 2020 Mar 24;2(4):235–242. doi: 10.1253/circrep.CR-19-0119

Figure 1.

Figure 1.

Subject selection. CTRCD, cancer therapy-related cardiovascular disorders; BL, baseline; FU, follow-up; HER2, human epidermal growth factor receptor-2; LVEF, left ventricular ejection fraction.